Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated.
This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.
Measurements:
The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients. | The inter-rater reliability, the test-retest reliability will be analyzed. | 3 months |
| The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients. | The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| The prevalence of depression in patients with schizophrenia | The point prevalence of depression in patients with schizophrenia will be presented in percentage. | 3 months |
| The association between depression in schizophrenia and quality of life. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Pariticipants diagnosed with schizophrenia according to DSM-IV-TR.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sirijit Suttajit, MD, MSc | Chiang Mai University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chiang Mai University | Chiang Mai | Chiang Mai | 50200 | Thailand |
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).
| 3 months |
| The association between depression in schizophrenia and type of antipsychotic drugs. | The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical). | 3 months |
| The association between depression in schizophrenia and severity of schizophrenia. | The association between depression in schizophrenia and severity of schizophrenia (PANSS score). | 3 months |